Triple Negative Breast Cancer Treatment Protocol

Early Stage TNBC (Stage I-III)

The American Society of Clinical Oncology recommends neoadjuvant therapy as a standard approach for stage II and III TNBC, allowing for tumor downstaging, assessment of pathologic complete response (pCR), and opportunity to tailor adjuvant therapy 1
The National Comprehensive Cancer Network suggests a preferred regimen for stage II/III TNBC: chemotherapy with taxanes, carboplatin, anthracyclines, and cyclophosphamide, combined with concurrent pembrolizumab 1
The European Society for Medical Oncology notes that the benefit from pembrolizumab is independent of PD-L1 status 1
Sequential anthracycline-based regimens followed by taxanes are an evidence-based alternative option, as recommended by the European Society for Medical Oncology 1, 2
For stage I TNBC, the American College of Surgeons suggests considering adding carboplatin and pembrolizumab for higher-risk disease 1
For patients with residual disease after standard neoadjuvant chemotherapy, adjuvant capecitabine for 6-8 cycles is recommended if germline BRCA1/2 wild-type, according to the National Comprehensive Cancer Network 1, 2
Regardless of response to neoadjuvant chemotherapy plus pembrolizumab, ongoing adjuvant pembrolizumab is recommended by the American Society of Clinical Oncology 1
For patients with germline BRCA1/2 mutations, PARP inhibitors may be considered in the adjuvant setting, as suggested by the Society of Gynecologic Oncology 3

For PD-L1-positive metastatic TNBC, the European Society for Medical Oncology recommends immune checkpoint inhibitor plus chemotherapy (atezolizumab plus nab-paclitaxel or pembrolizumab plus chemotherapy) 3, 4, 5
For PD-L1-negative metastatic TNBC, the American Society of Clinical Oncology prefers single-agent chemotherapy over combination chemotherapy, though combination regimens may be considered for symptomatic or immediately life-threatening disease 3, 4
Platinum-based or non-platinum-based regimens can be offered based on individual assessment, according to the National Comprehensive Cancer Network 3
For patients who have received at least two prior therapies for metastatic disease, the American College of Physicians strongly recommends sacituzumab govitecan 3, 4
For patients with germline BRCA1/2 mutations previously treated with chemotherapy, PARP inhibitors (olaparib or talazoparib) are preferred over chemotherapy, as suggested by the Society of Gynecologic Oncology 3, 4

Patients with TNBC should undergo genetic testing for germline BRCA1/2 mutations, according to the National Comprehensive Cancer Network 3
PARP inhibitors demonstrate high response rates in TNBC with DNA repair defects, including germline BRCA1/2 and PALB2 mutations, as noted by the American Society of Clinical Oncology 3

Regular follow-up with ipsilateral and contralateral mammography every 1-2 years is recommended by the European Society for Medical Oncology 6
No evidence that additional laboratory or imaging tests improve survival in asymptomatic patients, according to the American College of Radiology 6

The American Society of Clinical Oncology recommends carboplatin or docetaxel as first-line chemotherapy for metastatic triple-negative breast cancer, with overall response rates of 31.4% and 34.0%, respectively 7, 8
Taxane-based regimens are preferred first-line options for triple-negative breast cancer if not previously used, with a median progression-free survival of approximately 9-11 months 7, 8
Atezolizumab plus nab-paclitaxel in PD-L1-positive metastatic triple-negative breast cancer shows an overall response rate of 35% in the immunotherapy arm versus 5% in chemotherapy alone, with a median progression-free survival of 7.5 versus 5.0 months (HR 0.62) 9

Sacituzumab govitecan in heavily pretreated patients with triple-negative breast cancer demonstrates an overall response rate of 35% versus 5% with standard chemotherapy, with a median progression-free survival of 5.6 versus 1.7 months (HR 0.41, P < 0.001) 7, 8
PARP inhibitors, such as olaparib or talazoparib, in BRCA-mutated triple-negative breast cancer show high response rates, with a median progression-free survival of 7.0-8.6 months versus 4.2-5.6 months with standard chemotherapy 10, 11, 12

The National Comprehensive Cancer Network recommends considering BRCA1/2 mutation status and neoadjuvant versus metastatic setting when determining response rates to chemotherapy for triple-negative breast cancer 7, 8
First-line therapy shows better response rates than later lines, with progressive decline in efficacy with each subsequent treatment 7, 8

For newly diagnosed metastatic triple-negative breast cancer, the European Society for Medical Oncology recommends expecting an overall response rate of approximately 35% with immunotherapy plus chemotherapy if PD-L1-positive, and 31-34% with single-agent taxane or platinum if PD-L1-negative 7, 8, 9
For BRCA-mutated triple-negative breast cancer after prior chemotherapy, the American Society of Clinical Oncology recommends using PARP inhibitors, which offer superior outcomes with progression-free survival improvement of 40-60% compared to chemotherapy 10, 11, 12

The American Society of Clinical Oncology recommends that when carboplatin is added to anthracycline-taxane-based neoadjuvant chemotherapy, pathologic complete response rates increase significantly, though at the cost of increased toxicity, in patients with triple-negative breast cancer 13
The addition of pembrolizumab to standard neoadjuvant chemotherapy yields substantially higher pathologic complete response rates, with benefit independent of PD-L1 status, in patients with triple-negative breast cancer 13

The American Society of Clinical Oncology notes that sacituzumab govitecan in heavily pretreated patients demonstrates a dramatic overall response rate versus standard chemotherapy, with median progression-free survival of 5.6 versus 1.7 months, in patients with triple-negative breast cancer 14
For BRCA-mutated triple-negative breast cancer, the National Comprehensive Cancer Network recommends that PARP inhibitors show median progression-free survival of 7.0-8.6 months versus 4.2-5.6 months with standard chemotherapy, representing a 40-60% improvement 14

The European Society for Medical Oncology states that BRCA1/2 mutation status is a critical determinant of response, with BRCA-mutated tumors showing superior responses to platinum agents and PARP inhibitors, in patients with triple-negative breast cancer 13, 14